Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells
Open Access
- 1 September 2008
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (37) , 25628-25637
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- PPARs in the brainBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtinJournal of Neurochemistry, 2007
- Effects of Peroxisome Proliferator-Activated Receptor Gamma Agonists on Brain Glucose and Glutamate Transporters after Stress in RatsNeuropsychopharmacology, 2006
- A Role for Mitochondrial Dysfunction in Perpetuating Radiation-Induced Genomic InstabilityCancer Research, 2006
- PPARγ agonists as new therapeutic agents for the treatment of Alzheimer's diseaseExperimental Neurology, 2006
- Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicityBiochemical and Biophysical Research Communications, 2006
- Trolox and 17β-Estradiol Protect against Amyloid β-Peptide Neurotoxicity by a Mechanism That Involves Modulation of the Wnt Signaling PathwayJournal of Biological Chemistry, 2005
- [Ca2+] Signaling between Mitochondria and Endoplasmic Reticulum in Neurons Is Regulated by MicrotubulesJournal of Biological Chemistry, 2005
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Mitochondrial Ca2+ Uptake Depends on the Spatial and Temporal Profile of Cytosolic Ca2+ SignalsJournal of Biological Chemistry, 2001